China Approves Schering-Plough's Pegintron
Posted on: Thursday, 5 April 2007, 12:00 CDT
Schering-Plough said Thursday the Chinese government approved Pegintron for the treatment of patients with chronic hepatitis B.
The approval, which came from the Chinese State Food and Drug Administration, makes Pegintron the only pegylated interferon in China indicated for a 24-week treatment course. Hepatitis B is the most prevalent infectious disease in China and one of the leading causes of death.
Schering-Plough is pleased to offer this effective new treatment option for Chinese patients with chronic hepatitis B, a major public health problem in China, said Robert Spiegel, Schering-Plough's chief medical officer and senior vice president.
Approximately 120 million people are chronic carriers of the hepatitis B virus in China and more than 330,000 die from the disease annually.
Source: United Press International
Related Articles
- ANA598 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C Infection
- FDA Approves Gilead's Viread for Chronic Hepatitis B Treatment in Adults
- Pharmasset Nominates PSI-7851 As a Lead Development Candidate for the Treatment of Chronic Hepatitis C
- Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C
- R7128 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C Infection
- China: Hepatitis Treatment Fails to Keep Pace With Economy
- Idenix, Novartis Seek Approval for Chronic Hepatitis B Treatment
- China Releases Guidelines on Hepatitis B Treatment
- Gilead Sciences Announces Initiation of Phase III Clinical Program Evaluating Tenofovir Disoproxil Fumarate for the Treatment of Chronic Hepatitis B Virus
- FDA Approves Pegasys(R) As the First and Only Pegylated Interferon for the Treatment of Chronic Hepatitis B
 |
 |
User Comments (0)
RSS Feeds